ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 135 filers reported holding ARCUS BIOSCIENCES INC in Q2 2021. The put-call ratio across all filers is 4.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $90,504 | -19.7% | 5,042 | -9.1% | 0.06% | -17.9% |
Q2 2023 | $112,680 | +105.2% | 5,548 | +84.3% | 0.07% | +123.3% |
Q1 2023 | $54,902 | -36.3% | 3,010 | -27.7% | 0.03% | -33.3% |
Q4 2022 | $86,153 | -35.2% | 4,166 | -17.8% | 0.04% | -15.1% |
Q3 2022 | $133,000 | +4.7% | 5,068 | +0.8% | 0.05% | +12.8% |
Q2 2022 | $127,000 | +1.6% | 5,029 | +27.2% | 0.05% | -16.1% |
Q1 2022 | $125,000 | -26.0% | 3,954 | -5.4% | 0.06% | -12.5% |
Q4 2021 | $169,000 | -44.0% | 4,179 | -51.8% | 0.06% | -51.9% |
Q3 2021 | $302,000 | +20.8% | 8,664 | -4.9% | 0.13% | +29.1% |
Q2 2021 | $250,000 | -4.6% | 9,111 | -2.5% | 0.10% | -7.2% |
Q1 2021 | $262,000 | +9.6% | 9,348 | +1.7% | 0.11% | +12.1% |
Q4 2020 | $239,000 | +25.8% | 9,188 | -17.0% | 0.10% | -1.0% |
Q3 2020 | $190,000 | -39.1% | 11,075 | -12.1% | 0.10% | -32.4% |
Q2 2020 | $312,000 | -22.0% | 12,599 | -56.1% | 0.15% | +261.0% |
Q3 2018 | $400,000 | -34.3% | 28,669 | -42.4% | 0.04% | -92.4% |
Q2 2018 | $609,000 | – | 49,734 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |